Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60. https://doi.org/10.1182/blood-2017-09-806398.

Article  CAS  PubMed  Google Scholar 

Moreno C. Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematol Am Soc Hematol Educ Program. 2020;2020(1):33–40. https://doi.org/10.1182/hematology.2020000086.

Article  Google Scholar 

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–28. https://doi.org/10.1056/NEJMoa1812836.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burger JA, Barr PM, Robak T, Owen C, Ghia P, Tedeschi A, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34(3):787–98. https://doi.org/10.1038/s41375-019-0602-x.

Article  CAS  PubMed  Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–91. https://doi.org/10.1016/S0140-6736(20)30262-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1188–200. https://doi.org/10.1016/S1470-2045(20)30443-5.

Article  CAS  PubMed  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36. https://doi.org/10.1056/NEJMoa1815281.

Article  CAS  PubMed  Google Scholar 

Small S, Ma S. Frontline treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Targeted therapy vs. chemoimmunotherapy. Curr Hematol Malig Rep. 2021;16(4):325–35. https://doi.org/10.1007/s11899-021-00637-1.

Article  PubMed  Google Scholar 

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–43. https://doi.org/10.1056/NEJMoa1817073.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112–20. https://doi.org/10.1182/blood.2021014960.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zapatka M, Tausch E, Ozturk S, Yosifov DY, Seiffert M, Zenz T, et al. Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy. Haematologica. 2022;107(3):604–14. https://doi.org/10.3324/haematol.2020.265777.

Article  CAS  PubMed  Google Scholar 

Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473–9. https://doi.org/10.1200/JCO.2009.27.8762.

Article  PubMed  Google Scholar 

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–30. https://doi.org/10.1038/nature15395.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6. https://doi.org/10.1056/NEJM200012283432602.

Article  CAS  PubMed  Google Scholar 

Thompson PA, O'Brien SM, Xiao L, Wang X, Burger JA, Jain N, et al. beta2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer. 2016;122(4):565–73. https://doi.org/10.1002/cncr.29794.

Article  CAS  PubMed  Google Scholar 

Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98(1):181–6. https://doi.org/10.1182/blood.v98.1.181.

Article  CAS  PubMed  Google Scholar 

Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363(9403):105–11. https://doi.org/10.1016/S0140-6736(03)15260-9.

Article  CAS  PubMed  Google Scholar 

Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848–54.

Article  CAS  PubMed  Google Scholar 

Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995–1004. https://doi.org/10.1158/1078-0432.CCR-08-1630.

Article  CAS  PubMed  Google Scholar 

Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, et al. Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. Blood Adv. 2017;1(25):2433–43. https://doi.org/10.1182/bloodadvances.2017011262.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, et al. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. Eur J Haematol. 2018; https://doi.org/10.1111/ejh.13149.

Ahn IE, Tian X, Ipe D, Cheng M, Albitar M, Tsao LC, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39(6):576–85. https://doi.org/10.1200/JCO.20.00979.

Article  CAS  PubMed  Google Scholar 

Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019;6(7):e366–e74. https://doi.org/10.1016/S2352-3026(19)30085-7.

Article  PubMed  PubMed Central  Google Scholar 

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765–73. https://doi.org/10.3324/haematol.2019.224121.

Article  PubMed  PubMed Central  Google Scholar 

Abrisqueta P, Delgado J, Alcoceba M, Oliveira AC, Loscertales J, Hernandez-Rivas JA, et al. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC). Br J Haematol. 2020;190(6):854–63. https://doi.org/10.1111/bjh.16748.

Article  CAS  PubMed  Google Scholar 

Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343–51. https://doi.org/10.1200/JCO.2005.05.0187.

Article  CAS  PubMed  Google Scholar 

Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C, et al. An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter's Syndrome. Leuk Lymphoma. 2016;57(6):1474–7. https://doi.org/10.3109/10428194.2015.1099643.

Article  PubMed  Google Scholar 

Barnea Slonim L, Ma S, Behdad A, Chen Q. Pseudo-Richter transformation of chronic lymphocytic leukaemia/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall. Br J Haematol. 2020;191(1):e22–e5. https://doi.org/10.1111/bjh.16948.

Article  CAS  PubMed  Google Scholar 

Duhren-von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012;489(7415):309–12. https://doi.org/10.1038/nature11309.

Article  CAS  PubMed  Google Scholar 

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28(3):649–57. https://doi.org/10.1038/leu.2013.358.

Article  CAS  PubMed  Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. https://doi.org/10.1056/NEJMoa1215637.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23. https://doi.org/10.1056/NEJMoa1400376.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–63. https://doi.org/10.1002/ajh.25638.

Article  CAS  PubMed  PubMed Central